| Today's Top Story |  |  | | - Roche launches academic-industry stem cell initiative
Roche Holding and the Innovative Medicines Initiative are establishing StemBANCC, a new academic-industry collaboration that aims to use human induced pluripotent stem cells as tools for drug discovery and research. The project will include 10 drugmakers and 23 academic institutions studying the use of human iPS cells for the identification of drug targets and biomarkers and the screening of drug benefits and toxicology. "The aim of StemBANCC is to generate and characterize 1,500 high-quality human induced pluripotent stem cell lines derived from 500 patients that can be used by researchers to study a range of diseases including diabetes and dementia," project coordinator Martin Graf said. Genetic Engineering & Biotechnology News (12/5), GenomeWeb Daily News (free registration) (12/5)       | Health Care & Policy | | | | - FDA approves more drugs this year
Through November, the FDA approved 31 new drugs this year for conditions including rheumatoid arthritis, HIV, multiple sclerosis and cancer, the most since it approved 36 in 2004. For the fiscal year that ended Sept. 30 and using a more inclusive definition of new drugs, the agency said Wednesday that it granted 35 new approvals. The Wall Street Journal (12/5) - Retool drug discovery to increase development success
 Aslepios Bioresearch chief scientific adviser Frank Sams-Dodd writes about the relative merits of disease-based and target-based drug discovery in the context of an expensive and tough development environment. A disease-based approach may appear less cost-effective, but that changes if the costs are compared on a per-mechanism-tested basis, he writes. Pharmalot.com/Pharma Blog (12/4) | Company & Financial News | | | | - Benitec, uniQure sign cross-licensing deal
Benitec Biopharma granted uniQure the right to use its DNA-directed RNA interference technology to develop treatments for Huntington's disease as part of a nonexclusive cross-licensing deal. In exchange, Benitech obtained nonexclusive rights to use uniQure's AAV5 technology to develop a DNA-directed RNA interference treatment for hepatitis B. Genetic Engineering & Biotechnology News (12/5)  | Dell has your IT wish list covered.
Desktops, laptops and accessories. Save up to 35% on the latest technology for your medical practice. Enable workforce productivity with the budget-friendly Latitude E5430. It offers easy management and integration into an E-Family docking environment. Shop Now. |
  | Earn 30,000 American Airlines AAdvantage® Bonus Miles*
• Your first eligible checked bag is free for you and up to 4 traveling companions*
• Priority Boarding — Enjoy an enhanced boarding experience*
• Access to a CitiBusiness 24-hour Personal Business Assistant to help with travel, hotel and dining arrangements and more
*Learn more. |
  | Industrial & Environmental | | | | - U.K. researchers to look at biofuel potential of tobacco tree
Researchers at the Royal Holloway, University of London, have received a grant from the EU to study the biofuel potential of the tobacco tree. The plant's ability to thrive in areas with low rainfall and excessive heat "is a crucial factor," said Paul Fraser, a research fellow at Royal Holloway's School of Biological Sciences. "It means that growing this crop will not be in competition for land space with food crops." DomesticFuel.com (12/4)  | |  | | The Buzz(CORPORATE ANNOUNCEMENTS)
| |  | |  |
| News from BIO | | | | - Ship with FedEx
FedEx is now offering member companies discounts of up to 35% off select FedEx services, both U.S. and international services. The BIO program with FedEx is one of the many cost-savings programs offered by BIO through its Business Solutions program. There is no charge for BIO member companies to participate in any of the BIO Business Solutions programs -- it is a benefit of membership. Learn more about the BIO and FedEx program.
| SmartQuote | | | |  | To change one's life: Start immediately. Do it flamboyantly. No exceptions."
--William James,
American psychologist and philosopher  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Wednesday, December 05, 2012
- Tuesday, December 04, 2012
- Monday, December 03, 2012
- Friday, November 30, 2012
- Thursday, November 29, 2012
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2012 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment